Finance

Lists
CGEM:NASDAQ
Cullinan Therapeutics Inc
22,16 USD
-0,76%
(-0,17) 1D
22,16 USD
0,00% (0,00)
After hours
Closed: 3-сен., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGEM...
Open
22,39 USD
High
22,68 USD
Low
21,65 USD
Mkt. cap
1,43 млд
Avg. vol.
647,67 миң
Volume
524,12 миң
52-wk high
23,19 USD
52-wk low
5,68 USD
EPS
-3,41 USD
Beta
0,01
Shares outstanding
64,36 млн
No. of employees
109
Open
22,39 USD
High
22,68 USD
Low
21,65 USD
Mkt. cap
1,43 млд
Avg. vol.
647,67 миң
Volume
524,12 миң
52-wk high
23,19 USD
52-wk low
5,68 USD
EPS
-3,41 USD
Beta
0,01
Shares outstanding
64,36 млн
No. of employees
109
About Cullinan Therapeutics Inc
CEO-
Employees109
Founded2016
Headquarters-
Sector-
Analyst ratings
Based on 11 analysts giving stock ratings to CGEM in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CGEM in the last 3 months.
Highest
Current 22,16 USD
47,00 USD (+112,09%)
Average
34,11 USD (+53,93%)
Lowest
27,00 USD (+21,84%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Buy
Reiterated
30,00 USD
+35,4%
08/17/2026
David Dai
UBS
Buy
Maintained
27,00 USD
+21,8%
08/17/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
30,00 USD
+35,4%
08/17/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
28,00 USD
+26,4%
08/13/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
47,00 USD
+112,1%
08/14/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
08/13/2026
Samantha Semenkow
Citi
Buy
Maintained
33,00 USD
+48,9%
08/06/2026
Boris Peaker
JonesTrading
Buy
Maintained
36,00 USD
+62,5%
08/06/2026
Robert Driscoll
Wedbush
Buy
Reiterated
37,00 USD
+67%
07/29/2026
Julian Harrison
BTIG
Buy
Reiterated
39,00 USD
+76%
07/29/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
06/10/2026
Soumit Roy
JonesTrading
Buy
Maintained
36,00 USD
+62,5%
04/06/2026
Bradley Canino
Guggenheim
Buy
Reiterated
30,00 USD
+35,4%
03/10/2026
Last report
2026-ж., 6-авг.
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,81 USD / -0,85 USD
+4,85%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
41,97 млн
42,94 млн
42,12 млн
44,44 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,63 млн
12,31 млн
11,57 млн
12,82 млн
Operating expense
55,60 млн
55,26 млн
53,70 млн
57,25 млн
Total operating expenses
55,60 млн
55,26 млн
53,70 млн
57,25 млн
Operating income
-55,60 млн
-55,26 млн
-53,70 млн
-57,25 млн
Other non operating income
-108,00 миң
-69,00 миң
-62,00 миң
-98,00 миң
EBT including unusual items
-50,61 млн
-50,71 млн
-49,66 млн
-53,70 млн
EBT excluding unusual items
-50,61 млн
-50,71 млн
-49,66 млн
-53,70 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-50,61 млн
-50,71 млн
-49,66 млн
-53,70 млн
Net profit margin
-
-
-
-
Earnings per share
-0,77
-0,77
-0,75
-0,81
Interest and investment income
5,09 млн
4,62 млн
4,10 млн
3,65 млн
Interest expense
-
-
-
-
Net interest expenses
5,09 млн
4,62 млн
4,10 млн
3,65 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-55,52 млн
-55,18 млн
-53,62 млн
-57,18 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору